Avapritinib

small molecule

Identifier: CI-DRUG-00000087
Entity page: /drug/avapritinib ↗
Edges: 57

Neighbours: 18 cancers2 genes10 trials9 approvals
Drawn: 39 of 39 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Avapritinib approved for …APPROVED_FOR10 of 9
→ approved for	Gastrointestinal Stromal Tumorsubtype	supports	mesh_therapeutic_area	Gastrointestinal Stromal Tumor	1	Regulatory	ema	graph →
→ approved for	Health Canada · CA · 2024Marketed in Canada as AYVAKYT (DIN 02551764) under ATC L01EX18 AVAPRITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.

Avapritinib targets …TARGETS2 of 2
→ targets	PDGFRA	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	KIT	—	INHIBITOR	—	1	Curated	chembl	graph →

Avapritinib targets …TARGETS2 of 2

→ targets

PDGFRA

—

INHIBITOR

—

Curated

Avapritinib investigated for …INVESTIGATED_FOR6 of 6
→ investigated for	Gastrointestinal Stromal Tumorsubtype	unknown	4	Gastrointestinal Stromal Tumor	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Acute Myeloid Leukemiahematologic_malignancy	unknown	2	Acute Myeloid Leukemia	1	Curated	chembl	graph →
→ investigated for	Systemic Mastocytosishematologic_malignancy	unknown	2	Systemic Mastocytosis	1	Curated	chembl	graph →
→ investigated for	Mast Cell Leukemiahematologic_malignancy	unknown	2	Mast Cell Leukemia	1	Curated	chembl	graph →
→ investigated for	Gliomasubtype	unknown	1	Glioma	1	Curated	chembl	graph →

Avapritinib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 18show all (up to 200)
→ investigated in trials for	Gastrointestinal Stromal Tumorsubtype 7 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gastrointestinal Stromal Tumor	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Myeloid Leukemiahematologic_malignancy 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Myeloid Leukemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Acute Myeloid Leukemia 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Acute Myeloid Leukemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Aggressive Systemic Mastocytosis 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Aggressive Systemic Mastocytosis	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Childhood Acute Myeloid Leukemia 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Childhood Acute Myeloid Leukemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Core Binding Factor Acute Myeloid Leukemia 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Core Binding Factor Acute Myeloid Leukemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Indolent Systemic Mastocytosis 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Indolent Systemic Mastocytosis	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Solid Neoplasm 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Solid Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Mast Cell Leukemiahematologic_malignancy 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Mast Cell Leukemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Systemic Mastocytosis with an Associated Myeloid Neoplasm 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Systemic Mastocytosis with an Associated Myeloid Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Central Nervous System Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Central Nervous System Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colorectal Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Lung Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Mastocytosis 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Mastocytosis	1	Observed	clinicaltrials	graph →

Avapritinib studied in …STUDIED_INderived10 of 22show all (up to 200)
→ studied in	NCT07131059NA · recruiting MRD-positive AML Clinical Study · 22 trials list this drug (10 active)	—	—	Adult Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT04116541Phase 2 · recruiting A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. · 22 trials list this drug (10 active)	—	—	Malignant Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04771520Phase 2 · recruiting Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors · 22 trials list this drug (10 active)	—	—	Malignant Solid Neoplasm,Melanoma,Sarcoma+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT03580655Phase 2 · completed (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis · 22 trials list this drug (10 active)	—	—	Malignant Mastocytosis,Aggressive Systemic Mastocytosis,Mast Cell Leukemia+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT07255638recruiting A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany · 22 trials list this drug (10 active)	—	—	Indolent Systemic Mastocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT06327685Phase 1 · recruiting Avapritinib With Decitabine in Patients With SM-AHN · 22 trials list this drug (10 active)	—	—	Systemic Mastocytosis with an Associated Myeloid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05381753completed Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World · 22 trials list this drug (10 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT06748001Phase 4 · recruiting Avapritinib Rollover Study · 22 trials list this drug (10 active)	—	—	Systemic Mastocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT04773782Phase 1/Phase 2 · completed A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling · 22 trials list this drug (10 active)	—	—	Solid Neoplasm,Central Nervous System Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03731260Phase 2 · active not recruiting (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis · 22 trials list this drug (10 active)	—	—	Indolent Systemic Mastocytosis	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths